BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

788 related articles for article (PubMed ID: 15836566)

  • 1. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases.
    Tepper SJ; Bigal ME; Sheftell FD; Rapoport AM
    Headache; 2004 Sep; 44(8):794-800. PubMed ID: 15330826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM; Schim JD; Chippendale TJ
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin in migraine prophylaxis.
    Göbel H
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG; Diamond S; Diamond M; Urban G
    Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
    Schim J
    Curr Med Res Opin; 2004 Jan; 20(1):49-53. PubMed ID: 14741072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S; Tölle T; Straube A; Pfaffenrath V; Stefenelli U; Ceballos-Baumann A;
    Eur Neurol; 2009; 62(4):204-11. PubMed ID: 19622887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
    Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW
    Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A for the treatment of nummular headache: four case studies.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Mar; 48(3):442-7. PubMed ID: 18028377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Headache prophylaxis with BoNTA: patient characteristics.
    Silberstein SD; Marmura MJ; Shaw J; Yu S
    Headache; 2010 Jan; 50(1):63-70. PubMed ID: 19549156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study.
    Smuts JA; Schultz D; Barnard A
    Headache; 2004 Sep; 44(8):801-5. PubMed ID: 15330827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study.
    Schulte-Mattler WJ; Krack P;
    Pain; 2004 May; 109(1-2):110-4. PubMed ID: 15082132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botox therapy for refractory chronic migraine.
    Conway S; Delplanche C; Crowder J; Rothrock J
    Headache; 2005 Apr; 45(4):355-7. PubMed ID: 15836573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
    Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
    Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.